(BLCO) Bausch + Lomb - Overview
Stock: Contact Lenses, Drops, Vitamins, Pharmaceuticals, Surgical Devices
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.8% |
| Relative Tail Risk | -9.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -23.47 |
| Character TTM | |
|---|---|
| Beta | 1.312 |
| Beta Downside | 1.327 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.07% |
| CAGR/Max DD | 0.02 |
Description: BLCO Bausch + Lomb January 08, 2026
Bausch + Lomb Corp. (NYSE: BLCO) is an eye-health company headquartered in Vaughan, Canada, operating in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland and other international markets. The business is organized into three segments-Vision Care, Pharmaceuticals, and Surgical-and sells products through a mix of direct sales forces and independent distributors.
The Vision Care segment supplies a full spectrum of contact lenses, from daily disposables to therapeutic lenses used during post-surgical healing, along with lens-care solutions, eye vitamins, mineral supplements, and over-the-counter drops for allergies, dry eye and redness. This segment captures roughly 45 % of BLCO’s total revenue, reflecting the broader industry trend of a 5-6 % CAGR in global contact-lens sales driven by rising myopia prevalence and increased consumer willingness to pay for premium daily disposables.
The Pharmaceuticals segment markets both proprietary and generic drugs for post-operative care, glaucoma, ocular hypertension, dry eye, and retinal diseases. The Surgical segment provides intra-ocular lenses, phacoemulsification equipment, and other devices for cataract, corneal, vitreous and retinal procedures. Together, these two segments contribute about 55 % of revenue and benefit from an aging population that is expected to boost cataract surgeries by roughly 3 % annually through 2030.
Recent financial data (FY 2023) show total revenue of approximately $2.5 billion, with an adjusted EBITDA margin of 14 % and a free-cash-flow conversion rate near 70 %. Key economic drivers include discretionary-spending trends that affect contact-lens adoption, regulatory timelines for new ophthalmic drugs, and currency exposure given the company’s Euro- and Yen-denominated sales. An ongoing concern is the competitive pressure from low-cost generic lens manufacturers, which could compress margins if not offset by higher-margin premium products.
For a deeper quantitative breakdown, the ValueRay platform’s detailed financial models can help you assess BLCO’s upside potential.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -305.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -0.98 > 1.0 |
| NWC/Revenue: 19.27% < 20% (prev 21.93%; Δ -2.65% < -1%) |
| CFO/TA 0.01 > 3% & CFO 171.1m > Net Income -305.0m |
| Net Debt (4.64b) to EBITDA (509.0m): 9.12 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (354.2m) vs 12m ago 0.08% < -2% |
| Gross Margin: 59.45% > 18% (prev 0.61%; Δ 5884 % > 0.5%) |
| Asset Turnover: 36.39% > 50% (prev 34.66%; Δ 1.73% > 0%) |
| Interest Coverage Ratio: 0.19 > 6 (EBITDA TTM 509.0m / Interest Expense TTM 421.0m) |
Altman Z'' -0.01
| A: 0.07 (Total Current Assets 2.85b - Total Current Liabilities 1.90b) / Total Assets 13.83b |
| B: -0.06 (Retained Earnings -873.0m / Total Assets 13.83b) |
| C: 0.01 (EBIT TTM 81.0m / Avg Total Assets 13.67b) |
| D: -0.28 (Book Value of Equity -2.07b / Total Liabilities 7.33b) |
| Altman-Z'' Score: -0.01 = B |
Beneish M -2.93
| DSRI: 1.09 (Receivables 1.09b/943.0m, Revenue 4.98b/4.68b) |
| GMI: 1.02 (GM 59.45% / 60.89%) |
| AQI: 0.98 (AQ_t 0.67 / AQ_t-1 0.68) |
| SGI: 1.06 (Revenue 4.98b / 4.68b) |
| TATA: -0.03 (NI -305.0m - CFO 171.1m) / TA 13.83b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of BLCO shares?
Over the past week, the price has changed by +1.80%, over one month by -0.70%, over three months by +9.47% and over the past year by +5.85%.
Is BLCO a buy, sell or hold?
- StrongBuy: 3
- Buy: 3
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BLCO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.5 | 3.2% |
| Analysts Target Price | 17.5 | 3.2% |
| ValueRay Target Price | 17.1 | 0.5% |
BLCO Fundamental Data Overview February 03, 2026
P/S = 1.1887
P/B = 0.9283
P/EG = 0.6992
Revenue TTM = 4.98b USD
EBIT TTM = 81.0m USD
EBITDA TTM = 509.0m USD
Long Term Debt = 4.92b USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 4.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.64b USD (from netDebt column, last quarter)
Enterprise Value = 10.55b USD (5.91b + Debt 4.95b - CCE 310.0m)
Interest Coverage Ratio = 0.19 (Ebit TTM 81.0m / Interest Expense TTM 421.0m)
EV/FCF = -54.28x (Enterprise Value 10.55b / FCF TTM -194.5m)
FCF Yield = -1.84% (FCF TTM -194.5m / Enterprise Value 10.55b)
FCF Margin = -3.91% (FCF TTM -194.5m / Revenue TTM 4.98b)
Net Margin = -6.13% (Net Income TTM -305.0m / Revenue TTM 4.98b)
Gross Margin = 59.45% ((Revenue TTM 4.98b - Cost of Revenue TTM 2.02b) / Revenue TTM)
Gross Margin QoQ = 60.19% (prev 58.92%)
Tobins Q-Ratio = 0.76 (Enterprise Value 10.55b / Total Assets 13.83b)
Interest Expense / Debt = 2.04% (Interest Expense 101.0m / Debt 4.95b)
Taxrate = 21.0% (US default 21%)
NOPAT = 64.0m (EBIT 81.0m * (1 - 21.00%))
Current Ratio = 1.51 (Total Current Assets 2.85b / Total Current Liabilities 1.90b)
Debt / Equity = 0.77 (Debt 4.95b / totalStockholderEquity, last quarter 6.43b)
Debt / EBITDA = 9.12 (Net Debt 4.64b / EBITDA 509.0m)
Debt / FCF = -23.86 (negative FCF - burning cash) (Net Debt 4.64b / FCF TTM -194.5m)
Total Stockholder Equity = 6.43b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.23% (Net Income -305.0m / Total Assets 13.83b)
RoE = -4.75% (Net Income TTM -305.0m / Total Stockholder Equity 6.43b)
RoCE = 0.71% (EBIT 81.0m / Capital Employed (Equity 6.43b + L.T.Debt 4.92b))
RoIC = 0.57% (NOPAT 64.0m / Invested Capital 11.31b)
WACC = 6.59% (E(5.91b)/V(10.86b) * Re(10.75%) + D(4.95b)/V(10.86b) * Rd(2.04%) * (1-Tc(0.21)))
Discount Rate = 10.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.48%
Fair Price DCF = unknown (Cash Flow -194.5m)
EPS Correlation: -45.07 | EPS CAGR: -5.63% | SUE: -1.59 | # QB: 0
Revenue Correlation: 90.21 | Revenue CAGR: 6.80% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.07 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=11
EPS next Year (2026-12-31): EPS=0.80 | Chg30d=+0.023 | Revisions Net=+1 | Growth EPS=+51.2% | Growth Revenue=+6.0%